Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end of infusion. The dotted line indicates the 50 µg/mL trough level. Tomuzotuximab serum levels were above 50 µg/mL 1 week after the second infusion in four out of five patients who received 720 mg and 1 week after the first infusion in all three patients who received 900 mg tomuzotuximab.